Daily Archives

January 14, 2020

Home / January 14, 2020

How We Fail Black Patients in Pain

An expert looks at how false notions and hidden biases fuel inadequate treatment of minorities’ pain, highlighting the importance of removing as much individual discretion and bias as possible. The article includes resources clinicians and institutions can use to practice more equitable pain treatment, such as the CDC Guideline for Prescribing Opioids for Chronic Pain and AAPM’s guidance on implementing the CDC Guideline.

Continuous Nerve Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain

Brief Summary:A multimodal analgesic regimen including regional anesthesia is used at UPMC Shadyside for primary thoracic and major abdominal surgeries. The current standard-of-care regional anesthesia techniques include Erector Spinae Plane (ESP) block for video assisted thorascopic surgery (VATS) and Quadratus Lumborum (QL) block for major abdominal surgery. 

Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration

Abstract: Importance: Extended-release/long-acting (ER/LA) opioids have caused substantial morbidity and mortality in the United States, yet little is known about the efforts of the US Food and Drug Administration (FDA) and drug manufacturers to reduce adverse outcomes associated with inappropriate prescribing or use.

Mechanisms of Affective Touch in Chronic Pain

Brief Summary:This study compares how different types of touch found in massage therapies impact pain perception, and whether these effects differ in individuals with and without chronic pain. This study also examines psychological factors that may predict differences in touch perception in individuals with chronic pain. This research will improve our understanding of whether and how massage therapies can benefit pain and health, and whether this differs in people who suffer from chronic pain.

Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with a History of Inadequate Response

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-07, Axsome’s novel, oral, multi-mechanistic investigational medicine for the acute treatment of migraine, met the two regulatory co-primary endpoints and significantly improved migraine pain and most bothersome symptoms as compared to placebo in the MOMENTUM Phase 3 trial.

Trends in Opioid Prescribing and Self-Reported Pain Among US Adults.

Abstract: Clinically informed efforts to curb inappropriate opioid prescribing seek to reduce prescribing to adults with lower pain levels that are potentially manageable with alternative therapies. According to the Medical Expenditure Panel Survey, the annual share of US adults who were prescribed opioids decreased from 12.9 percent in 2014 to 10.3 percent in 2016, and the decrease was concentrated among adults with shorter-term rather than longer-term prescriptions. 

Identification of Spinal Afferent Nerve Endings in the Colonic Mucosa and Submucosa That Communicate Directly With the Spinal Cord: The Gut-Brain Axis.

 Abstract: The major sensory nerve pathway between the colon and central nervous system (spinal cord and brain) that underlies the gut-brain axis, is via spinal afferent neurons, with cell bodies in dorsal root ganglia (DRG). Our aim was to identify the sensory nerve endings in the colon that arise from single colorectal-projecting DRG neurons. C57BL/6 mice were anesthetized and lumbosacral L6-S1 DRG injected with dextran biotin. Mice recovered for 7 days. 

1 2 3
Pain Medicine Journal
Access to this page is restricted to members only! Not a mamber? Join Now!

Ask Us Anything. Anytime.

📝 Fill in your details and we’ll get back to you in no time.
AAPM

American Academy of Pain Medicine